Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FSCE7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $72,660
Award facts
- Contract value 100% obligated
- $72,659.87 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $72,659.87 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. This firm fixed-price delivery order was issued on January 22, 2026, with an ultimate completion date of February 12, 2026, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued without subcontractor involvement, with performance to occur at the vendor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.999 billion acquisition strategy established to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, features a 30-month base period with three additional 30-month option periods extending through December 31, 2036, and authorizes DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and specialized medical products. The MACI implant sheets represent a specialty surgical product within the contractor's comprehensive pharmaceutical and medical consumables portfolio supplied to military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FSCE7?
SPE2DR26FSCE7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FSCE7 worth?
The government has obligated $72,660 on SPE2DR26FSCE7.
Is contract SPE2DR26FSCE7 an order under another contract?
Yes. SPE2DR26FSCE7 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCE7 competed?
The extent of competition for SPE2DR26FSCE7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award